Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

SS-LUP-332 Oral vs Injectable: Route Comparison

The table below compares SS-LUP-332 oral vs injectable across bioavailability, onset, dosing, and practical research factors. Bioavailability 15–25% (gastric degradation + first-pass metabolism) 95–100% (bypasses GI tract and liver) Injectable delivers 3–5× hi

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • The table below compares SS-LUP-332 oral vs injectable across bioavailability, onset, dosing, and practical research factors.
  • Bioavailability
  • 15–25% (gastric degradation + first-pass metabolism)
  • 95–100% (bypasses GI tract and liver)
  • Injectable delivers 3–5× higher plasma concentration at equivalent doses
  • Onset of Action
  • 90–150 minutes (depends on gastric emptying)
  • 30–60 minutes (direct systemic absorption)
  • Injectable produces measurable effects 2–3× faster
  • Peak Plasma Concentration
  • Lower and more variable (affected by food, pH)
  • Higher and more predictable (minimal variability)
  • Injectable provides more consistent experimental conditions
  • Typical Dose Range
  • 10–50 mg (compensates for low absorption)
  • 2–10 mg (higher bioavailability = lower dose needed)
  • Oral requires 3–5× higher dose to approximate injectable plasma levels
  • Storage Requirements
  • Room temperature stable (15–25°C, 12–24 months)
  • Lyophilised: −20°C; reconstituted: 2–8°C, 28 days
  • Oral formulations simplify storage logistics
  • Administration Complexity
  • Simple (oral ingestion, no special technique)
  • Moderate (requires sterile technique, injection training)
  • Oral is faster and easier for large-scale studies
  • Metabolic Effect Magnitude
  • Moderate (blunted by low bioavailability)
  • High (full dose reaches target tissues)
  • Injectable produces stronger thermogenic response at lower doses
  • Safety Margin
  • Wider (most of dose never reaches circulation)
  • Narrower (nearly all administered dose is bioavailable)
  • Oral formulations are more forgiving of dosing errors